Equities research analysts expect Medidata Solutions Inc (NASDAQ:MDSO) to post sales of $162.57 million for the current fiscal quarter, according to Zacks . Seven analysts have issued estimates for Medidata Solutions' earnings. The lowest sales estimate is $161.40 million and the highest is $163.96 million. Medidata Solutions reported sales of $140.08 million during the same quarter last year, which indicates a positive year-over-year growth rate of 16.1%. The firm is expected to issue its next quarterly earnings results on Thursday, October 25th.
On average, analysts expect that Medidata Solutions will report full year sales of $637.34 million for the current financial year, with estimates ranging from $635.30 million to $641.40 million. For the next year, analysts expect that the company will post sales of $760.82 million per share, with estimates ranging from $738.90 million to $779.24 million. Zacks' sales calculations are a mean average based on a survey of sell-side research firms that cover Medidata Solutions. Get Medidata Solutions alerts:
Medidata Solutions (NASDAQ:MDSO) last announced its earnings results on Tuesday, July 24th. The company reported $0.43 EPS for the quarter, topping the Zacks' consensus estimate of $0.39 by $0.04. The business had revenue of $155.90 million during the quarter, compared to the consensus estimate of $155.86 million. Medidata Solutions had a net margin of 9.13% and a return on equity of 11.37%. The firm's revenue was up 14.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.31 earnings per share.
MDSO has been the subject of a number of recent research reports. Needham & Company LLC boosted their target price on shares of Medidata Solutions to $80.00 and gave the stock a "buy" rating in a report on Friday, April 20th. Zacks Investment Research downgraded shares of Medidata Solutions from a "buy" rating to a "hold" rating in a report on Thursday, April 26th. BidaskClub upgraded shares of Medidata Solutions from a "hold" rating to a "buy" rating in a report on Friday, May 4th. Dougherty & Co reiterated a "buy" rating and issued a $89.00 target price (up from $79.00) on shares of Medidata Solutions in a report on Thursday, May 10th. Finally, Morgan Stanley downgraded shares of Medidata Solutions from an "overweight" rating to a "hold" rating and set a $79.00 target price for the company. in a report on Monday, May 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. The company presently has an average rating of "Buy" and a consensus price target of $86.93.
Shares of Medidata Solutions stock opened at $78.94 on Friday. The stock has a market capitalization of $4.63 billion, a price-to-earnings ratio of 92.87, a PEG ratio of 4.87 and a beta of 1.40. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.16. Medidata Solutions has a one year low of $59.60 and a one year high of $88.87.
In other news, EVP Michael I. Otner sold 9,288 shares of the business's stock in a transaction dated Tuesday, July 24th. The stock was sold at an average price of $81.03, for a total transaction of $752,606.64. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink . Also, Director Lee Shapiro sold 12,500 shares of the business's stock in a transaction dated Thursday, July 26th. The stock was sold at an average price of $76.16, for a total value of $952,000.00. Following the sale, the director now owns 26,028 shares in the company, valued at approximately $1,982,292.48. The disclosure for this sale can be found here . Insiders have sold 39,418 shares of company stock worth $3,086,728 in the last 90 days. Insiders own 4.70% of the company's stock.
Hedge funds have recently modified their holdings of the company. Champlain Investment Partners LLC boosted its position in Medidata Solutions by 15.7% in the first quarter. Champlain Investment Partners LLC now owns 2,148,615 shares of the company's stock valued at $134,955,000 after buying an additional 291,630 shares during the last quarter. Janus Henderson Group PLC boosted its position in Medidata Solutions by 69.7% in the second quarter. Janus Henderson Group PLC now owns 1,904,094 shares of the company's stock valued at $153,394,000 after buying an additional 782,194 shares during the last quarter. American Century Companies Inc. boosted its position in Medidata Solutions by 3.5% in the second quarter. American Century Companies Inc. now owns 1,494,796 shares of the company's stock valued at $120,421,000 after buying an additional 50,370 shares during the last quarter. Canada Pension Plan Investment Board boosted its position in Medidata Solutions by 2.8% in the second quarter. Canada Pension Plan Investment Board now owns 1,111,500 shares of the company's stock valued at $89,542,000 after buying an additional 29,800 shares during the last quarter. Finally, Fred Alger Management Inc. boosted its position in Medidata Solutions by 87.3% in the second quarter. Fred Alger Management Inc. now owns 1,068,170 shares of the company's stock valued at $86,052,000 after buying an additional 497,817 shares during the last quarter.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
Get a free copy of the Zacks research report on Medidata Solutions (MDSO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Medidata Solutions Medidata Solution